Stockscreener 앱 받기
19.48
4.06%
0.765
전일 마감가:
$18.71
열려 있는:
$18.67
하루 거래량:
2.49M
Relative Volume:
0.28
시가총액:
$10.01B
수익:
$10.89B
순이익/손실:
$-241.00M
주가수익비율:
-73.32
EPS:
-0.2656
순현금흐름:
$340.00M
1주 성능:
-10.40%
1개월 성능:
-0.92%
6개월 성능:
-19.25%
1년 성능:
-36.41%
1일 변동 폭
$18.61
$19.63
1주일 범위
$18.57
$22.41
52주 변동 폭
$17.40
$37.74
박스터 인터내셔널 Stock (BAX) Company Profile
명칭
Baxter International Inc
전화
(224) 948-2000
주소
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
19.48 | 9.62B | 10.89B | -241.00M | 340.00M | -0.2656 |
|
ISRG
Intuitive Surgical Inc
|
490.02 | 169.97B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
177.22 | 50.58B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.24 | 38.58B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.79 | 37.11B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
252.60 | 35.80B | 5.40B | 1.49B | 1.78B | 10.12 |
박스터 인터내셔널 Stock (BAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 다운그레이드 | Argus | Buy → Hold |
| 2025-08-04 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-08-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-26 | 재개 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | Argus | Hold → Buy |
| 2025-02-20 | 재개 | Barclays | Overweight |
| 2024-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-12-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-06-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-18 | 재확인 | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-18 | 재확인 | Raymond James | Outperform |
| 2022-02-18 | 재확인 | Stifel | Buy |
| 2022-02-18 | 재확인 | UBS | Neutral |
| 2022-02-18 | 재확인 | Wells Fargo | Overweight |
| 2022-02-11 | 개시 | Goldman | Neutral |
| 2022-01-07 | 재개 | Citigroup | Buy |
| 2022-01-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-09-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-12-15 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-09-04 | 다운그레이드 | Argus | Buy → Hold |
| 2020-06-24 | 개시 | Oppenheimer | Outperform |
| 2020-03-19 | 업그레이드 | Stifel | Hold → Buy |
| 2020-03-18 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-13 | 개시 | Goldman | Buy |
| 2020-01-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-01-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-01-02 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | 업그레이드 | Argus | Hold → Buy |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-05-17 | 재개 | Piper Jaffray | Overweight |
| 2018-02-06 | 재확인 | Citigroup | Neutral |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
모두보기
박스터 인터내셔널 주식(BAX)의 최신 뉴스
Baxter sales up 8% to USD 2.97B in Q4 2025 - Medical Buyer
Baxter's new CEO mired in damage control before he can address long-term problems - Crain's Chicago Business
Baxter Stock (-16%): Profit Guidance Collapse Triggers De-Risking - Trefis
Baxter International Is Quietly Going Off – But Is BAX Stock Really Worth Your Money? - AD HOC NEWS
Decoding Baxter International Inc (BAX): A Strategic SWOT Insigh - GuruFocus
Baxter International (BAX) Q4 2025 Sales Exceed Expectations, EPS Falls Short - GuruFocus
Baxter International Earnings Call: Growth Meets Margin Squeeze - TipRanks
Baxter is the S&P 500’s worst performer today. Earnings were brutal. - MSN
BAXTER INTERNATIONAL INC SEC 10-K Report - TradingView
Baxter International Inc (BAX) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Pressures - GuruFocus
Baxter stock dives on Q4 EPS miss, company introduces new operating model - massdevice.com
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Baxter International: Debt, Margin Pressure, Dreadful FY26 Guidance (Downgrade) (NYSE:BAX) - Seeking Alpha
Baxter shares tumble 16% on weak earnings - breakingthenews.net
Baxter International Stock Falls Sharply. Earnings Were Brutal. - Barron's
Baxter International Q4 Earnings Call Highlights - Yahoo Finance
Key facts: Baxter International appoints McDonnell; reports Q4 loss - TradingView
Baxter Turnaround Efforts Continue, but Outcome Remains Uncertain - Morningstar
Why Baxter International Stock Was Tumbling Today - Yahoo Finance
Baxter annual profit forecast disappoints as key product troubles mount - marketscreener.com
Why Baxter International Stock Was Tumbling Today - The Motley Fool
Baxter forecast 2026 profit below estimates - marketscreener.com
Baxter (BAX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Baxter Shares Tank, 2026 Profit Guidance Lower Than ExpectedBaxter Intl (NYSE:BAX) - Benzinga
BAX Stock Falls Following Q4 Earnings Miss, Margins Contract - The Globe and Mail
Baxter Faces Legal Claims Amid Financial Uncertainty - StocksToTrade
Baxter CEO: ‘We need to get better’ - Modern Healthcare News
Baxter International Faces Potential Legal Claims Amid Stock Concerns - timothysykes.com
Baxter International Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Baxter’s Q4 2025 results miss EPS forecast, stock drops By Investing.com - Investing.com India
Baxter slips following Q4 bottom line miss, weak 2026 EPS guidance - MSN
Baxter Q4 2025 slides: Revenue grows 8% but margins compress, EPS misses target By Investing.com - Investing.com India
Baxter International (BAX) Sees Market Activity Rise - GuruFocus
Legal Concerns Loom Over Baxter Amid Fiduciary Duty Accusations - StocksToTrade
Baxter (BAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Australia
Baxter Shares Plunge on Dismal Financial Outlook - AD HOC NEWS
Baxter International (BAX) Q4 Earnings Lag Estimates - Yahoo Finance
Baxter International Inc (NYSE:BAX) Stock Plummets on Q4 Earnings Miss and Weak 2026 Outlook - ChartMill
Baxter: Q4 Earnings Snapshot - kens5.com
Baxter: Fourth Quarter Financial Overview - bitget.com
Baxter International Q4 Adjusted Earnings Fall, Net Sales Rise; 2026 Guidance Issued - marketscreener.com
BAXTER INTERNATIONAL ($BAX) Releases Q4 2025 Earnings - Quiver Quantitative
Baxter shares plunge 14% after earnings miss, weak profit guidance By Investing.com - Investing.com Nigeria
Baxter Int'l Provides Weak FY26 Outlook As Q4 Adj. EPS Misses Estimates; Stock Tumbles 14.6% - Nasdaq
Baxter International Reports Mixed Q4 Results and Outlook - TipRanks
Earnings Flash (BAX) Baxter International Inc. Reports Q4 Revenue $2.97B, vs. FactSet Est of $2.82B - marketscreener.com
S&P 500 Futures Climb in Premarket Trading; Icon PLC, Baxter International Lag - Barron's
Baxter sales climb, but $2.01 EPS loss and flat 2026 outlook loom - Stock Titan
FMR LLC's Strategic Acquisition of Baxter International Inc. Sha - GuruFocus
A senior executive at Baxter International recently pointed out that the company’s first-quarter business still faces ongoing challenges caused by the return of Novum infusion devices. - Bitget
Baxter earnings ahead: Can medical device maker reverse losses? By Investing.com - Investing.com Nigeria
박스터 인터내셔널 (BAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
자본화:
|
볼륨(24시간):